Single-Cell tech could unlock secrets of a highly effective vaccine
NCT ID NCT03458780
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This pilot study tests a new technology called inDrop RNA-Seq to analyze individual immune cells in detail. Researchers will use it to study how healthy adults respond to the yellow fever vaccine, which is known to be very effective. The goal is to identify the specific cell types and genes that drive a strong immune response, which could help improve future vaccines.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- yellow fever vaccine (YF-Vax)
- What this could lead to
- If successful, this could reveal which cell types and genes are key for a strong vaccine response, potentially guiding better vaccine design.
- What could go wrong
- This is a very small pilot study with only 6 participants, so findings may not apply broadly. The technology is also new and unproven for this purpose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
6 people
The number who actually took part.
- Started
-
Aug 2016
- Finished
-
Sep 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy Volunteers
- Ages
-
18 to 59 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female between the ages of 18 and 59 years old * Volunteers who have not received a vaccination within 30 days of the YFV and do not anticipate to receive a vaccination within 30 days * Volunteers who are seeking the YFV for either travel reasons or occupational risk * Volunteers willing to undergo one screening visit, one visit to receive the YFV, and four post-vaccination visits * Volunteers without medical conditions who are willing to give blood once for the development of the inDrop technique Exclusion Criteria: * Male or females under 18 or over 59 years of age * Volunteers who received other vaccination less than 30 days prior to receiving the YFV * Volunteers with acute or febrile disease * Volunteers unable to return for the post vaccination follow-up visits * Volunteers with an allergy to eggs, chicken proteins, gelatin, or other components of the Yellow Fever vaccine * Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study * Is pregnant or lactating * Volunteers with a history of yellow fever vaccination and/or infection * Volunteers with a history of viral hepatitis and/or non-viral liver disease * In the opinion of the investigators, the volunteer is unlikely to comply with the study protocol * Immunosuppressed individuals as a result of cancer, transplantation, and or primary immunodeficiency * Immunosuppressed individuals as a result of medications (such as high-dose systemic corticosteroids, alkylating drugs, antimetabolites, TNF-α inhibitors (e.g., etanercept), IL-1 blocking agents (e.g., anakinra), and other monoclonal antibodies targeting immune cells (e.g.,rituximab, alemtuzumab) and/or radiation * Volunteers with thymus disorders (including myasthenia gravis, Di George syndrome, or thymoma) and/or history of thymectomy * Individuals infected with HIV
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Rockefeller University
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The effects of external nasal dilator strips on sleep and cardiovascular health
- A pharmacokinetic study of NTI164 in healthy adult volunteers
- Genetic determinants of Exercise-Induced muscle damage (POLYGENDOMUS) / déterminants génétiques des dommages musculaires induits par l'Exercice (POLYGENDOMUS)
- Can a simple injection timing reduce bleeding after skin cancer surgery?
- Can Land-Based teachings shape psychedelic therapy training?
- Can a new oral drug pass early safety tests?